Search

Displaying results 4431 - 4440 of 10000 in total
  1. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    [A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions. … It is currently under investigation for the treatment osteoarthritic pain[A241045] and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e

    Categories: Analgesics, Non-Narcotic
  2. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  3. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC). … The initial target market is haemodialysis graft access surgery, a procedure in which patients whose kidneys have failed have a plastic tube grafted between blood vessels generally in their forearm so

  4. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

    Synonyms: N-methylhyoscine bromide, N-methylscopolammonium bromide
  5. Drug

    DTS-201

    go.drugbank.com/drugs/DB06071
    Experimental

    DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. … DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which

  6. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    Quinupristin

    go.drugbank.com/drugs/DB01369
    Approved

    The combination of the two components acts synergistically and is more effective in vitro than each component alone. … Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

  8. Drug

    Arrhenatherum elatius pollen

    go.drugbank.com/drugs/DB10879
    Approved

    Arrhenatherum elatius pollen is the pollen of the Arrhenatherum elatius plant. Arrhenatherum elatius pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Standardized and Non-Standardized Coastal Grasses, Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  9. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. … If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD.

  10. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking … On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection.